Repurchase Frenzy Heats Up: Over 100 Pharma Companies Announce Buybacks in Two Months

　　【Pharmaceutical Network | Pharmaceutical Stock Market] Recently, Sino Biopharm announced that it plans to repurchase its ordinary shares in the open market within 12 months for no more than HK$2 billion. In the announcement, the board of directors of Sino Biopharm stated that the company has sufficient financial resources to implement the share buyback plan and maintain a sound financial position. "Conducting share buybacks under the current circumstances demonstrates the company's confidence in its business outlook and prospects, and will ultimately benefit the company and create value for shareholders."
 

This share repurchase primarily aims to boost investor confidence and enhance shareholder returns as soon as possible. In fact, since the beginning of this year, Sino Biopharm has cumulatively repurchased approximately 60.35 million shares, at a cost of around HK$338 million.
 

Notably, data shows that since the beginning of this year, pharmaceutical companies listed on the A-share and H-share markets have cumulatively repurchased shares worth nearly RMB 13 billion. Among them, from early April to mid-June, more than 100 pharmaceutical listed companies on the A-share and H-share markets announced or implemented share repurchases.
 

As disclosed in Tigermed’s “Announcement on Progress of Share Repurchase Reaching 2% of Total Share Capital” released on June 19, the company had completed the repurchase of 2% of its total share capital under its share repurchase plan as of June 16, 2026. It is reported that, pursuant to the repurchase plan, the company intends to use its own funds or self-raised funds to repurchase a portion of its A-shares through centralized bidding and other methods, for the purposes of subsequent equity incentives, employee stock ownership plans, or cancellation to reduce registered capital. The total amount of funds for the repurchase shall be no less than RMB 500 million and no more than RMB 1 billion, with an implementation period of 12 months from the date of approval by the shareholders’ meeting.
 

Brii Biosciences announced on June 17 that the Board of Directors has resolved to utilize no more than HK$60 million to repurchase shares in the open market, with the mandate extending until the next Annual General Meeting of Shareholders (2027). The Board believes that the current share price is undervalued, and this move aims to convey confidence in the company’s business prospects and create value for shareholders. Meanwhile, the Board stated that, leveraging its existing financial resources, the Company can implement the share repurchase plan while maintaining a robust financial position.
 

From May 26 to June 12, WuXi AppTec repurchased H-shares for 14 consecutive trading days, with a cumulative total of 18.4383 million shares repurchased at an amount of HK$2.282 billion. Notably, on June 12 alone, the company repurchased 2.3012 million shares at prices ranging from HK$121.2 to HK$127.3 per share, amounting to HK$289 million. It is worth noting that the company recently disclosed a new RMB 1 billion A-share repurchase plan, intended for use in its employee stock ownership plan.
 

Akeso announced on June 11 that the Board of Directors had approved the use of HK$200 million to repurchase the Company’s ordinary shares in the open market. The announcement stated that the share buyback is driven by strong confidence in the Group’s long-term investment value, robust R&D capabilities, and ability to drive continuous innovation, and will be funded from its own financial resources.
 

Biokin announced on June 2 that it would repurchase a portion of its issued RMB ordinary shares (A-shares) through centralized bidding transactions, using its own funds and/or self-raised funds. The total amount of funds intended for the repurchase shall be no less than RMB 100 million (inclusive) and no more than RMB 200 million (inclusive). The repurchased shares will be entirely used to implement employee stock ownership plans or equity incentives at an appropriate time in the future.
 

　　……
 

Industry observers believe that the surge in mergers and acquisitions among pharmaceutical companies since 2026 marks a transition in the sector from an external capital-driven “cash-burn model” to a “value management” phase driven by commercial self-sustainability. In the future, an increasing number of pharmaceutical enterprises are expected to generate stable cash flows and deliver returns to shareholders.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.